These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 28353284)

  • 1. Models of LRRK2-Associated Parkinson's Disease.
    Xiong Y; Dawson TM; Dawson VL
    Adv Neurobiol; 2017; 14():163-191. PubMed ID: 28353284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological Functions of LRRK2 in Parkinson's Disease.
    Jeong GR; Lee BD
    Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review.
    Chen ML; Wu RM
    J Biomed Sci; 2018 Jun; 25(1):52. PubMed ID: 29903014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.
    Chittoor-Vinod VG; Villalobos-Cantor S; Roshak H; Shea K; Abalde-Atristain L; Martin I
    J Neurosci; 2020 Aug; 40(32):6234-6249. PubMed ID: 32605938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
    Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
    Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration.
    Yang D; Thomas JM; Li T; Lee Y; Liu Z; Smith WW
    Biochem Cell Biol; 2018 Aug; 96(4):441-449. PubMed ID: 29268033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in the mouse.
    Giesert F; Glasl L; Zimprich A; Ernst L; Piccoli G; Stautner C; Zerle J; Hölter SM; Vogt Weisenhorn DM; Wurst W
    Neurobiol Dis; 2017 Sep; 105():179-193. PubMed ID: 28576705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2(I2020T) functional genetic interactors that modify eye degeneration and dopaminergic cell loss in Drosophila.
    Marcogliese PC; Abuaish S; Kabbach G; Abdel-Messih E; Seang S; Li G; Slack RS; Haque ME; Venderova K; Park DS
    Hum Mol Genet; 2017 Apr; 26(7):1247-1257. PubMed ID: 28158614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse models for LRRK2 Parkinson's disease.
    Xu Q; Shenoy S; Li C
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
    Lu YW; Tan EK
    J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.
    Gómez-Suaga P; Fdez E; Fernández B; Martínez-Salvador M; Blanca Ramírez M; Madero-Pérez J; Rivero-Ríos P; Fuentes JM; Hilfiker S
    Neuropharmacology; 2014 Oct; 85():45-56. PubMed ID: 24863040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease.
    Islam MS; Nolte H; Jacob W; Ziegler AB; Pütz S; Grosjean Y; Szczepanowska K; Trifunovic A; Braun T; Heumann H; Heumann R; Hovemann B; Moore DJ; Krüger M
    Hum Mol Genet; 2016 Dec; 25(24):5365-5382. PubMed ID: 27794539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.
    Thakur G; Kumar V; Lee KW; Won C
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 links genetic and sporadic Parkinson's disease.
    Kluss JH; Mamais A; Cookson MR
    Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
    Daniëls V; Baekelandt V; Taymans JM
    Neurosignals; 2011; 19(1):1-15. PubMed ID: 21430363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.